EP3964504A4 - Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon - Google Patents
Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon Download PDFInfo
- Publication number
- EP3964504A4 EP3964504A4 EP20798155.6A EP20798155A EP3964504A4 EP 3964504 A4 EP3964504 A4 EP 3964504A4 EP 20798155 A EP20798155 A EP 20798155A EP 3964504 A4 EP3964504 A4 EP 3964504A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation
- benzothiophene compound
- benzothiophene
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910359616 | 2019-04-30 | ||
| PCT/CN2020/085525 WO2020221038A1 (zh) | 2019-04-30 | 2020-04-20 | 苯并噻吩类化合物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3964504A1 EP3964504A1 (de) | 2022-03-09 |
| EP3964504A4 true EP3964504A4 (de) | 2022-12-28 |
Family
ID=73028761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20798155.6A Pending EP3964504A4 (de) | 2019-04-30 | 2020-04-20 | Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12269816B2 (de) |
| EP (1) | EP3964504A4 (de) |
| JP (1) | JP7531508B2 (de) |
| KR (1) | KR102885020B1 (de) |
| CN (2) | CN118108716A (de) |
| WO (1) | WO2020221038A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3149482A1 (en) | 2019-08-02 | 2021-02-11 | Mersana Therapeutics, Inc. | Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer |
| WO2021113679A1 (en) * | 2019-12-06 | 2021-06-10 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
| WO2021202984A1 (en) | 2020-04-02 | 2021-10-07 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| CN115772154B (zh) * | 2021-09-08 | 2024-04-30 | 上海交通大学 | 一类含有氘取代的苯并噻吩类衍生物及其制备与用途 |
| CN119212984A (zh) * | 2022-04-25 | 2024-12-27 | 密歇根大学董事会 | Sting激动剂、制剂及其用途 |
| WO2024032782A1 (en) * | 2022-08-12 | 2024-02-15 | Jacobio Pharmaceuticals Co.Ltd. | Vaccine adjuvants and uses thereof |
| CN115950995B (zh) * | 2022-12-02 | 2026-01-13 | 中国石油大学(北京) | 一种分离石油油品中噻吩类化合物的方法及其应用 |
| WO2025096584A1 (en) * | 2023-10-30 | 2025-05-08 | The Regents Of The University Of Michigan | Sting agonists, compositions, and uses thereof |
| CN119219600B (zh) * | 2024-08-06 | 2025-09-26 | 国家纳米科学中心 | 一种sting激动剂msa-2的水溶性前药化合物及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019069275A1 (en) * | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | STING AGONIST ADMINISTRATION METHODS |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| UA92450C2 (ru) * | 2003-01-14 | 2010-11-10 | Арена Фармасьютикалз, Инк. | 1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия |
| BRPI0815096A2 (pt) | 2007-07-18 | 2015-07-14 | Janssen Pharmaceutica Nv | Sulfonamidas como moduladores de trpm8 |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | タンパク質調節物質として有用な複素環アミド |
| US10414747B2 (en) | 2016-10-04 | 2019-09-17 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene compounds as sting agonists |
| JP2018067423A (ja) | 2016-10-18 | 2018-04-26 | パナソニックIpマネジメント株式会社 | グリップセンサ |
| PE20200696A1 (es) * | 2017-06-22 | 2020-06-16 | Curadev Pharma Ltd | Moduladores de moleculas pequenas de sting humana |
| JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドCuradev Pharma Limited | ヒトstingの複素環式小分子調節因子 |
| US20200138827A1 (en) | 2017-06-22 | 2020-05-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
| JP2019027857A (ja) | 2017-07-27 | 2019-02-21 | トヨタ自動車株式会社 | ネジゲージ取り外し冶具 |
| US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
| US11312772B2 (en) | 2017-08-04 | 2022-04-26 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment |
| US10793557B2 (en) * | 2018-04-03 | 2020-10-06 | Merck Sharp & Dohme Corp. | Sting agonist compounds |
-
2020
- 2020-04-20 EP EP20798155.6A patent/EP3964504A4/de active Pending
- 2020-04-20 CN CN202410249613.2A patent/CN118108716A/zh active Pending
- 2020-04-20 KR KR1020217027710A patent/KR102885020B1/ko active Active
- 2020-04-20 JP JP2021551542A patent/JP7531508B2/ja active Active
- 2020-04-20 US US17/435,031 patent/US12269816B2/en active Active
- 2020-04-20 WO PCT/CN2020/085525 patent/WO2020221038A1/zh not_active Ceased
- 2020-04-20 CN CN202080017726.XA patent/CN113518776B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019069275A1 (en) * | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | STING AGONIST ADMINISTRATION METHODS |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220162199A1 (en) | 2022-05-26 |
| WO2020221038A1 (zh) | 2020-11-05 |
| JP7531508B2 (ja) | 2024-08-09 |
| JP2022530936A (ja) | 2022-07-05 |
| CN113518776B (zh) | 2024-03-26 |
| CN118108716A (zh) | 2024-05-31 |
| CN113518776A (zh) | 2021-10-19 |
| US12269816B2 (en) | 2025-04-08 |
| KR20220004013A (ko) | 2022-01-11 |
| EP3964504A1 (de) | 2022-03-09 |
| KR102885020B1 (ko) | 2025-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4011886A4 (de) | Tetrazyklische verbindung, herstellungsverfahren dafür und verwendung da | |
| EP3964504A4 (de) | Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon | |
| EP3816150A4 (de) | M-diamid-verbindung sowie herstellungsverfahren dafür und verwendung davon | |
| EP3889154A4 (de) | Zwischenprodukt einer heterozyklischen verbindung, verfahren zu ihrer herstellung und ihre verwendung | |
| EP4043464A4 (de) | Kondensierte pyridonverbindung, herstellungsverfahren dafür und verwendung davon | |
| MA54471A (fr) | Composé agoniste de récepteur thrb, son procédé de préparation et son utilisation | |
| EP4194449A4 (de) | Heterocyclische verbindung, herstellungsverfahren dafür und verwendung davon | |
| EP4053118A4 (de) | Substituierte heterocyclische kondensierte cyclische verbindung, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung | |
| EP3778579A4 (de) | Aromatische verbindung sowie herstellungsverfahren dafür und verwendung davon | |
| EP3967687A4 (de) | Substituiertes phenylpropenylpyridinderivat und herstellungsverfahren dafür und medizinische verwendung davon | |
| EP3517535A4 (de) | Alkynyl-substituierte heterocyclische verbindung, herstellungsverfahren dafür und medizinische verwendung davon | |
| EP3660019A4 (de) | Verbindung sowie ihre herstellung und verwendung | |
| EP4006024A4 (de) | Heterozyklische amidverbindung, herstellungsverfahren dafür und verwendung davon | |
| EP3640248A4 (de) | Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon | |
| EP3828168A4 (de) | Quaternäre ammoniumverbindung und verfahren zu ihrer herstellung und verwendung | |
| EP3828169A4 (de) | Dikationsverbindung, herstellungsverfahren dafür und verwendung davon | |
| EP3964518A4 (de) | Cd73-inhibitor, herstellungsverfahren dafür und anwendungen davon | |
| EP3556761A4 (de) | Pyrrolo-aromatische heterocyclische verbindung, herstellungsverfahren dafür und medizinische verwendung davon | |
| EP3998265A4 (de) | Ret-selektiver inhibitor, herstellungsverfahren dafür und verwendung davon | |
| EP4137483A4 (de) | Heterocyclische benzolitrierverbindung, herstellungsverfahren dafür und verwendung davon | |
| EP4063363A4 (de) | Pyrazolheteroarylderivat, herstellungsverfahren dafür und medizinische verwendung davon | |
| EP3967682A4 (de) | Bisheterocyclische carbonyl-substituierte dihydropyrazolverbindung, herstellungsverfahren dafür und pharmazeutische verwendung davon | |
| EP4119546A4 (de) | Bifunktionelle verbindung, herstellungsverfahren dafür und verwendung davon | |
| EP4063453A4 (de) | Polypropylenzusammensetzung, herstellungsverfahren dafür und verwendung davon | |
| EP3858833A4 (de) | Aminonordekanderivat und herstellungsverfahren dafür und anwendung davon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20210830 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20221125 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20221121BHEP Ipc: A61K 31/4155 20060101ALI20221121BHEP Ipc: A61K 31/381 20060101ALI20221121BHEP Ipc: C07D 409/14 20060101ALI20221121BHEP Ipc: C07D 333/64 20060101AFI20221121BHEP |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230428 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20260216 |